| Study Period | 2019 - 2030 |
| Market Size (2025) | USD 26.95 Billion |
| Market Size (2030) | USD 39.37 Billion |
| CAGR (2025 - 2030) | 7.88 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
| Market Concentration | Medium |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Chronic Pain Treatment Market Analysis
The Chronic Pain Treatment Market size is estimated at USD 26.95 billion in 2025, and is expected to reach USD 39.37 billion by 2030, at a CAGR of 7.88% during the forecast period (2025-2030).
The chronic pain treatment market is driven by key factors such as the increasing prevalence of chronic pain, technological advancements in both drugs and devices, and the growing geriatric population.
The rising prevalence of chronic pain is a significant driver for the market's growth. For example, a report published by the Centers for Disease Control and Prevention in November 2024 revealed that in 2023, 24.3% of adults experienced chronic pain, with 8.5% reporting high-impact chronic pain that severely disrupted daily activities or work. Women were disproportionately affected, with 25.4% experiencing chronic pain and 9.6% suffering from high-impact chronic pain, compared to 23.2% and 7.3% among men, respectively. This increasing prevalence, particularly among women, is fueling the demand for innovative and effective chronic pain management solutions. The growing burden of pain-related limitations is driving advancements in treatment options, thereby contributing to the expansion of the chronic pain treatment market.
Additionally, the expanding geriatric population is expected to accelerate market growth further. According to a report by the World Health Organization published in October 2024, by 2030, one in six individuals globally will be aged 60 years or older, with the population in this age group projected to grow from 1 billion in 2020 to 1.4 billion. By 2050, this demographic is anticipated to double to 2.1 billion, while the population aged 80 years or older is expected to triple, reaching 426 million. This growing elderly population, which is more prone to age-related chronic pain conditions, is significantly increasing the demand for effective chronic pain treatment solutions, thereby driving market growth.
Furthermore, advancements in technology are also playing a crucial role in propelling the chronic pain treatment market. For instance, in February 2023, Anglo-French Drugs & Industries Ltd. introduced AFD-NP, a product combining Nortriptyline and Pregabalin, designed to manage moderate to severe neuropathic pain. Experts have highlighted the superior efficacy of this combination therapy, particularly in Indian clinical settings, compared to alternatives involving Nortriptyline and Gabapentin. This innovation is expected to enhance treatment outcomes and address unmet therapeutic needs in neuropathy management, thereby expanding the market.
In conclusion, the chronic pain treatment market is witnessing substantial growth, driven by the increasing prevalence of chronic pain, the rising geriatric population, and advancements in innovative therapeutic solutions to address unmet patient needs. However, the high costs associated with advanced therapies in both drugs and devices and the potential side effects of pain management drugs are anticipated to act as restraints on market growth.
Chronic Pain Treatment Market Trends
The Neuropathic Pain Segment is Expected to Witness Significant Growth Over the Forecast Period
Neuropathic pain, a chronic condition, results from damage to the nervous system and is associated with various underlying health issues, including diabetes, shingles, and spinal cord injuries. This condition significantly impacts a large global population, leading to substantial disability and a marked decline in quality of life. The neuropathic pain segment is experiencing robust growth, primarily driven by the increasing prevalence of chronic diseases such as diabetes and cancer, which are major risk factors for neuropathic pain. This trend is generating a strong demand for effective treatment and management solutions.
The aging population is another critical factor contributing to the market's expansion, as older individuals are more prone to age-related conditions like diabetic neuropathy and postherpetic neuralgia. For example, a report published by the Instituto Nazionale di Statistica in September 2024 revealed that Italy's elderly population grew from 23.8% in 2022 to 24.3% in 2024. Similarly, a study published in Frontiers in Clinical Diabetes and Healthcare in January 2023 highlighted the rising prevalence of diabetic peripheral neuropathy (DPN), which affects a significant proportion of diabetic patients. With approximately 50% of diabetic patients projected to develop DPN, the increasing incidence of this irreversible and debilitating condition, particularly in low- and middle-income regions, underscores the urgent need for effective pain management solutions. The growing burden of DPN is driving the expansion of the neuropathic pain treatment segment as patients seek therapies to improve their quality of life and mitigate complications such as non-traumatic limb amputations. These demographic trends are expected to sustain the demand for advanced neuropathic pain therapies.
Moreover, technological advancements in the neuropathic pain segment are also expected to propel the growth of the segment in the chronic pain treatment market. These advancements are enhancing treatment efficacy and broadening the spectrum of available options. For instance, in December 2023, Vertex Pharmaceuticals Incorporated announced positive Phase 2 results for its selective NaV1.8 inhibitor, VX-548, demonstrating significant reductions in pain intensity among individuals with painful diabetic peripheral neuropathy (DPN). The treatment exhibited a favorable safety profile, with only mild to moderate adverse events and no serious adverse events associated with VX-548. This breakthrough in DPN treatment is anticipated to drive growth in the neuropathic pain treatment segment within the chronic pain treatment market by providing a promising new option for pain management.
Similarly, in January 2023, Abbott received U.S. Food and Drug Administration (FDA) approval for its Proclaim XR spinal cord stimulation (SCS) system, designed to treat painful diabetic peripheral neuropathy (DPN), a severe complication of diabetes. This system offers an alternative to traditional treatments, such as oral medications, and integrates with Abbott's NeuroSphere Virtual Clinic, enabling remote physician consultations and treatment adjustments. This innovation is expected to propel growth in the neuropathic pain treatment segment of the chronic pain treatment market by delivering advanced, remote-access solutions to patients requiring effective care options.
In conclusion, the neuropathic pain treatment market is witnessing significant growth, driven by the rising prevalence of chronic conditions, an aging population, and technological advancements that offer innovative and effective solutions for pain management.
Understand The Key Trends Shaping This Market
Download PDF
North America is Expected to Hold a Significant Share in the Market Over the Forecast Period
North America is anticipated to experience significant growth in the chronic pain treatment market, driven by its well-established pharmaceutical industry, particularly in the United States and Canada, and the rapid adoption of innovative treatment solutions.
The increasing prevalence of cancer-related pain in the region is a key factor contributing to this market expansion. According to a study published in the Cancers (Basel) Journal in January 2023, 44.5% of cancer patients in the region suffer from pain, highlighting a growing demand for effective pain management solutions. Furthermore, 30.6% of these patients endure moderate to severe pain. Combined with advancements in pain management practices and treatment guidelines, this underscores an urgent need for advanced therapeutic options. These factors, along with progress in oncology and pain management, are driving the growth of the chronic pain treatment market.
Moreover, rising regional investments and government-led initiatives are expected to propel market growth further. For example, in November 2022, the Government of Canada announced funding exceeding CAD 5 million (USD 3.50 million) to enhance support for individuals with chronic pain and expand the Pain Canada Network. This funding includes nearly CAD 4.5 million (USD 3.13 million) allocated to Pain BC’s initiative to broaden the network and improve education and training, as well as over CAD 520,000 (USD 361,515) dedicated to developing a program addressing chronic pain in diverse communities. These initiatives aim to improve access to care, foster national collaboration, and address the needs of underserved populations, thereby driving the growth of the chronic pain treatment market.
The increasing focus on key regional market players is also expected to contribute significantly to market expansion. For instance, in March 2023, Nevro Corp announced the full market launch of its HFX iQ spinal cord stimulation (SCS) system in the United States following a successful limited release. The HFX iQ system integrates clinical data and Quality of Life metrics to deliver personalized treatment settings tailored to individual patient needs, including pain relief, medication usage, and activity levels. This advancement in personalized chronic pain management is anticipated to significantly enhance the efficacy and customization of pain therapies, thereby driving market growth.
In conclusion, factors such as the rising prevalence of chronic pain, increasing government initiatives, and strategic activities by key companies are expected to drive robust growth in North America's chronic pain treatment market during the forecast period.
Get Analysis on Important Geographic Markets
Download PDF
Chronic Pain Treatment Industry Overview
The chronic pain treatment market is fragmented and comprises several prominent players. In terms of market share, a few key companies currently hold a dominant position. However, mid-sized and smaller firms are expanding their market presence by leveraging technological advancements and offering innovative products. Leading companies in the market include Pfizer Inc., Medtronic PLC, Abbott Laboratories, Novartis AG, Becton, Dickinson, and Company, among others.
Chronic Pain Treatment Market Leaders
-
Pfizer Inc.
-
Medtronic PLC
-
Abbott Laboratories
-
Novartis AG
-
Becton, Dickinson, and Company
- *Disclaimer: Major Players sorted in no particular order
Need More Details on Market Players and Competiters?
Download PDF
Chronic Pain Treatment Market News
- April 2024: Medtronic plc secured approval from the U.S. Food and Drug Administration (FDA) for its Inceptiv closed-loop rechargeable spinal cord stimulator (SCS), developed to address chronic pain. This approval represents a significant milestone as Medtronic's first SCS device to feature a closed-loop system. The device can detect biological signals along the spinal cord and autonomously adjust stimulation in real-time, ensuring the therapy remains responsive to the patient’s daily movements.
- April 2024: Vertex Pharmaceuticals Incorporated advanced its suzetrigine pain program, a potential breakthrough in treating acute and neuropathic pain. Following the positive Phase 3 trial results for acute pain reported in January 2024, the FDA has granted a rolling New Drug Application (NDA) submission for suzetrigine, targeting the management of moderate-to-severe acute pain.
Chronic Pain Treatment Industry Segmentation
As per the scope of this report, encompasses a range of treatments, including pharmaceuticals and medical devices, aimed at alleviating persistent pain conditions that significantly impact patients' quality of life. The chronic pain treatment market is segmented by product type, application, end-user, and geography. The product type segment is further divided into drugs, and devices. The drugs segment is further segmented into Non-Narcotic Analgesics. The Non-Narcotic Analgesics segment is further divided into non-Steroidal anti-Inflammatory drugs, anesthetics, anticonvulsants, antidepressants, and other non-narcotic analgesics. The device segment is further divided into neurostimulation devices, and analgesic infusion umps. The neurostimulation devices segment is further segmented into transcutaneous electrical nerve stimulation devices, and brain and spinal cord stimulation devices. The analgesic infusion pumps segment is further divided into intrathecal infusion umps, and external infusion pumps. The application segment is further segmented into neuropathic pain, arthritic pain, post-surgical pain, cancer pain, and others . The other application is further divided into joint pain, musculoskeletal pain, among others. The end-user segment is divided into hospitals, clinics, and other end-users. The geography segment is divided into North America, Europe, Asia-Pacific, Middle East and Africa, and South America. The report also covers the estimated market sizes and trends for 17 countries across major regions globally. The report offers the value (in USD) for the above segments.
| By Product Type | Drugs | Non-Narcotic Analgesics | Non-Steroidal Anti-Inflammatory Drugs | |
| Anesthetics | ||||
| Anticonvulsants | ||||
| Antidepressants | ||||
| Other Non-Narcotic Analgesics | ||||
| Devices | Neurostimulation Devices | Transcutaneous Electrical Nerve Stimulation Devices | ||
| Brain and Spinal Cord Stimulation Devices | ||||
| Analgesic Infusion Pumps | Intrathecal Infusion Pumps | |||
| External Infusion Pumps | ||||
| By Application | Neuropathic Pain | |||
| Arthritic Pain | ||||
| Post-Surgical Pain | ||||
| Cancer Pain | ||||
| Others | ||||
| End- User | Hospitals and Clinics | |||
| Other End Users | ||||
| Geography | North America | United States | ||
| Canada | ||||
| Mexico | ||||
| Europe | Germany | |||
| United Kingdom | ||||
| France | ||||
| Italy | ||||
| Spain | ||||
| Rest of Europe | ||||
| Asia-Pacific | China | |||
| Japan | ||||
| India | ||||
| Australia | ||||
| South Korea | ||||
| Rest of Asia-Pacific | ||||
| Middle-East and Africa | GCC | |||
| South Africa | ||||
| Rest of Middle-East and Africa | ||||
| South America | Brazil | |||
| Argentina | ||||
| Rest of South America | ||||
Need A Different Region or Segment?
Customize Now
Chronic Pain Treatment Market Research FAQs
How big is the Chronic Pain Treatment Market?
The Chronic Pain Treatment Market size is expected to reach USD 26.95 billion in 2025 and grow at a CAGR of 7.88% to reach USD 39.37 billion by 2030.
What is the current Chronic Pain Treatment Market size?
In 2025, the Chronic Pain Treatment Market size is expected to reach USD 26.95 billion.
Who are the key players in Chronic Pain Treatment Market?
Pfizer Inc., Medtronic PLC, Abbott Laboratories, Novartis AG and Becton, Dickinson, and Company are the major companies operating in the Chronic Pain Treatment Market.
Which is the fastest growing region in Chronic Pain Treatment Market?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2025-2030).
Which region has the biggest share in Chronic Pain Treatment Market?
In 2025, the North America accounts for the largest market share in Chronic Pain Treatment Market.
What years does this Chronic Pain Treatment Market cover, and what was the market size in 2024?
In 2024, the Chronic Pain Treatment Market size was estimated at USD 24.83 billion. The report covers the Chronic Pain Treatment Market historical market size for years: 2019, 2020, 2021, 2022, 2023 and 2024. The report also forecasts the Chronic Pain Treatment Market size for years: 2025, 2026, 2027, 2028, 2029 and 2030.
